ATE442847T1 - Benzimidazol-derivate als mek-hemmer - Google Patents
Benzimidazol-derivate als mek-hemmerInfo
- Publication number
- ATE442847T1 ATE442847T1 AT04744015T AT04744015T ATE442847T1 AT E442847 T1 ATE442847 T1 AT E442847T1 AT 04744015 T AT04744015 T AT 04744015T AT 04744015 T AT04744015 T AT 04744015T AT E442847 T1 ATE442847 T1 AT E442847T1
- Authority
- AT
- Austria
- Prior art keywords
- benzimidazole derivatives
- mek inhibitors
- derivatives
- mek
- inhibitors
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49001203P | 2003-07-24 | 2003-07-24 | |
| PCT/IB2004/002355 WO2005009975A2 (en) | 2003-07-24 | 2004-07-12 | Benzimidazole derivatives as mek inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE442847T1 true ATE442847T1 (de) | 2009-10-15 |
Family
ID=34102957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04744015T ATE442847T1 (de) | 2003-07-24 | 2004-07-12 | Benzimidazol-derivate als mek-hemmer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7160915B2 (de) |
| EP (1) | EP1651214B1 (de) |
| JP (1) | JP4896717B2 (de) |
| AT (1) | ATE442847T1 (de) |
| BR (1) | BRPI0412851A (de) |
| CA (1) | CA2532067C (de) |
| DE (1) | DE602004023207D1 (de) |
| ES (1) | ES2331246T3 (de) |
| MX (1) | MXPA06000921A (de) |
| WO (1) | WO2005009975A2 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| CN101247806B (zh) | 2005-06-23 | 2012-05-16 | 阵列生物制药公司 | 用于制备苯并咪唑化合物的SNAr方法 |
| ES2567133T3 (es) * | 2005-06-23 | 2016-04-20 | Array Biopharma, Inc. | Proceso para preparar compuestos de benzoimidazol |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| DE602006021205D1 (de) | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| JP5311673B2 (ja) | 2006-12-14 | 2013-10-09 | エグゼリクシス， インコーポレイテッド | Ｍｅｋ阻害剤の使用方法 |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| US7557221B2 (en) | 2007-08-16 | 2009-07-07 | Hoffman-La Roche Inc. | Substituted hydantoins |
| WO2009037705A2 (en) * | 2007-09-20 | 2009-03-26 | Ramot At Tel Aviv University Ltd. | Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation |
| US8765815B2 (en) | 2007-09-20 | 2014-07-01 | Ramot At Tel-Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
| CA2705452C (en) | 2007-11-12 | 2016-05-31 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| MX2010006331A (es) | 2007-12-20 | 2010-07-05 | Hoffmann La Roche | Hidantoinas sustituidas como inhibidores de cinasa mek. |
| EP2240494B1 (de) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Thienopyridin-derivate als mek-hemmer |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| EP2307364B1 (de) * | 2008-07-01 | 2013-06-19 | Genentech, Inc. | Isoindolonderivate als mek-kinase-inhibitoren und anwendungsverfahren |
| WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| US20120172351A1 (en) | 2009-06-09 | 2012-07-05 | Nobuyuki Negoro | Novel fused cyclic compound and use thereof |
| CA2777430A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| JP2013508318A (ja) | 2009-10-21 | 2013-03-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 置換されたベンゾスルホンアミド誘導体 |
| US20120263714A1 (en) | 2009-10-21 | 2012-10-18 | Bayer Intellectual Property Gmbh | Substituted halophenoxybenzamide derivatives |
| MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CN104394855A (zh) | 2012-05-31 | 2015-03-04 | 拜耳医药股份有限公司 | 用于测定肝细胞癌(hcc)患者的治疗的有效响应的生物标记 |
| JP6300042B2 (ja) | 2012-10-12 | 2018-03-28 | エグゼリクシス， インコーポレイテッド | 癌の処置に使用するための化合物の製造方法 |
| HRP20240033T1 (hr) * | 2012-10-19 | 2024-03-29 | Array Biopharma, Inc. | Formulacija koja sadrži inhibitor mek |
| CN111518031B (zh) * | 2020-05-29 | 2023-01-17 | 中国药科大学 | 一种含有异羟肟酸的化合物及其制备方法、应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| IL132840A (en) | 1997-07-01 | 2004-12-15 | Warner Lambert Co | Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors |
| US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| IL125425A (en) | 1998-07-20 | 2008-12-29 | Israel State | ADPGPPase CONTROL OF STARCH SYNTHESIS IN TOMATOES |
| EP1143957A3 (de) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Mek inhibitoren zur behandlung von arthritis |
| HRP20010524A2 (en) * | 1999-01-13 | 2002-08-31 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| CN1373660A (zh) * | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| CA2377092A1 (en) * | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| CA2439263C (en) * | 2001-03-02 | 2012-10-23 | Frank Becker | Three hybrid assay system |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| RU2300528C2 (ru) | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
-
2004
- 2004-07-12 EP EP04744015A patent/EP1651214B1/de not_active Expired - Lifetime
- 2004-07-12 DE DE602004023207T patent/DE602004023207D1/de not_active Expired - Lifetime
- 2004-07-12 BR BRPI0412851-6A patent/BRPI0412851A/pt not_active IP Right Cessation
- 2004-07-12 MX MXPA06000921A patent/MXPA06000921A/es unknown
- 2004-07-12 CA CA2532067A patent/CA2532067C/en not_active Expired - Fee Related
- 2004-07-12 JP JP2006520928A patent/JP4896717B2/ja not_active Expired - Fee Related
- 2004-07-12 ES ES04744015T patent/ES2331246T3/es not_active Expired - Lifetime
- 2004-07-12 AT AT04744015T patent/ATE442847T1/de not_active IP Right Cessation
- 2004-07-12 WO PCT/IB2004/002355 patent/WO2005009975A2/en not_active Ceased
- 2004-07-22 US US10/897,464 patent/US7160915B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4896717B2 (ja) | 2012-03-14 |
| JP2006528621A (ja) | 2006-12-21 |
| CA2532067A1 (en) | 2005-02-03 |
| WO2005009975A2 (en) | 2005-02-03 |
| CA2532067C (en) | 2010-12-21 |
| DE602004023207D1 (de) | 2009-10-29 |
| EP1651214A2 (de) | 2006-05-03 |
| US7160915B2 (en) | 2007-01-09 |
| US20050026970A1 (en) | 2005-02-03 |
| EP1651214B1 (de) | 2009-09-16 |
| ES2331246T3 (es) | 2009-12-28 |
| BRPI0412851A (pt) | 2006-10-03 |
| WO2005009975A3 (en) | 2005-04-07 |
| MXPA06000921A (es) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE442847T1 (de) | Benzimidazol-derivate als mek-hemmer | |
| ATE532781T1 (de) | 5-(acylamino)indazol-derivate als kinase- inhibitoren | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
| NO20063821L (no) | Kinolinderivater for anvendelse som mykobakterielle inhibitorer | |
| DE60305724D1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| EA200700192A1 (ru) | Производные фталазина в качестве ингибиторов parp | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| EA200500299A1 (ru) | Пиразольные композиции, используемые в качестве ингибиторов gsk-3 | |
| BRPI0515477A (pt) | derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd) | |
| ATE484508T1 (de) | Furylverbindungen | |
| UA99485C2 (ru) | Хиназолиндионовые производные, их получение и их применение в терапии | |
| NO20054848L (no) | Substituerte p-diaminobenzenderivater | |
| ATE413877T1 (de) | Indol-derivate und ihre verwendung als kinase- hemmer, insbesondere ikk2-hemmer | |
| TW200508207A (en) | New benzimidazole derivatives | |
| SE0403171D0 (sv) | New compounds | |
| ATE355265T1 (de) | Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren | |
| ATE478054T1 (de) | Benzimidazolderivate | |
| NO20054340L (no) | Nye sammenkoplede heterocykler og deres anvendelse | |
| ATE396970T1 (de) | 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri | |
| SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| EA200600100A1 (ru) | Производные никотинамида, полезные в качестве ингибиторов pde4 | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| NO20072078L (no) | Indolderivater som inhibitorer av loselig adenylsyklase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |